[HTML][HTML] Targeting PI3K/Akt signal transduction for cancer therapy
Y He, MM Sun, GG Zhang, J Yang, KS Chen… - Signal transduction and …, 2021 - nature.com
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays a crucial role in various
cellular processes and is aberrantly activated in cancers, contributing to the occurrence and …
cellular processes and is aberrantly activated in cancers, contributing to the occurrence and …
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
JA Engelman - Nature Reviews Cancer, 2009 - nature.com
There are ample genetic and laboratory studies that suggest the PI3K–Akt pathway is vital to
the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the …
the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the …
Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy
YL Chen, PY Law, HH Loh - Current Medicinal Chemistry-Anti …, 2005 - ingentaconnect.com
The phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B, PKB) signaling pathway
plays a critical role in cell growth and survival. Dysregulation of this pathway has been found …
plays a critical role in cell growth and survival. Dysregulation of this pathway has been found …
Targeting the PI3K signaling pathway in cancer therapy
C Bartholomeusz… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: The PI3K signaling pathway is involved in the regulation of cancer cell growth,
motility, survival and metabolism. The pathway is frequently active in many different types of …
motility, survival and metabolism. The pathway is frequently active in many different types of …
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
NT Ihle, G Powis - Molecular cancer therapeutics, 2009 - AACR
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is currently one of
the most exciting drug targets in oncology. However, only a short time ago, the paradigm …
the most exciting drug targets in oncology. However, only a short time ago, the paradigm …
The PI3K pathway as drug target in human cancer
KD Courtney, RB Corcoran… - Journal of clinical oncology, 2010 - ascopubs.org
The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth,
survival, motility, and metabolism. This pathway is activated by several different mechanisms …
survival, motility, and metabolism. This pathway is activated by several different mechanisms …
[HTML][HTML] Targeting PI3K in cancer: mechanisms and advances in clinical trials
Abstract Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
signaling is one of the most important intracellular pathways, which can be considered as a …
signaling is one of the most important intracellular pathways, which can be considered as a …
PI3K/AKT signaling pathway and cancer: an updated review
Despite development of novel agents targeting oncogenic pathways, matching targeted
therapies to the genetic status of individual tumors is proving to be a daunting task for …
therapies to the genetic status of individual tumors is proving to be a daunting task for …
Targeting the phosphoinositide 3-kinase pathway in cancer
P Liu, H Cheng, TM Roberts, JJ Zhao - Nature reviews Drug discovery, 2009 - nature.com
Abstract The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system
that links oncogenes and multiple receptor classes to many essential cellular functions, and …
that links oncogenes and multiple receptor classes to many essential cellular functions, and …
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
N Vasan, LC Cantley - Nature Reviews Clinical Oncology, 2022 - nature.com
Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …